NERV stock on watch as FDA declines NDA for schizophrenia drug (NASDAQ:NERV)
seekingalpha.com
news
2022-10-17 13:04:56

Grandbrothers Updated to add the share move after the trading halt. Minerva Neurosciences (NASDAQ:NERV), a biotech focused on central nervous system diseases, announced Monday that the FDA issued a "refusal to file" letter regarding its marketing application for roluperidone, a treatment targeted at schizophrenia patients. After a brief trading halt, NERV shares dropped ~65% in reaction to the news. Without detailing reasons for the refusal, NERV said that the FDA had notified the company could request a Type A meeting to discuss the contents of the letter.
